Summit Therapeutics Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 36.6 million compared to USD 19.3 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.07 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.65 USD | -2.72% | +5.92% | +78.16% |
07/05 | Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target | MT |
01/05 | Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024 |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+78.16% | 3.26B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- SMMT Stock
- News Summit Therapeutics Inc.
- Summit Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023